CLC Bio said this week that the Center for Cancer Computational Biology at the Dana-Farber Cancer Institute has selected CLC's enterprise platform to handle its next-generation sequence analysis needs.
Mick Correll, associate director of the CCCB, said the institute deployed CLC Bio's platform to support an "increasing number of molecular biologists and clinicians who don't have their own bioinformatics resources."
CLC Bio's platform provides "versatile deployment opportunities," he said. "By giving individual groups access to our central installation of the CLC Genomics Server, they can leverage a powerful enterprise platform while only needing to invest in their own desktop clients."
Currently, Dana-Farber os building the data-coordination and -analysis informatics infrastructure for the Lung Genomics Research Consortium, which aims to add genetic, genomic, and epigenetic data and analysis tools to an existing clinical biorepository at the National Heart Lung and Blood Institute (BI 02/11/2011).